Blood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 Carriers-Reference-Cited by-同舟云学术

Blood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 Carriers

Published:2024-06-06 Issue:11 Volume:16 Page:1788
ISSN:2072-6643
Container-title:Nutrients
language:en
Short-container-title:Nutrients

Author:

Kiljańczyk Adam¹,Matuszczak Milena¹^ORCID,Marciniak Wojciech²^ORCID,Derkacz Róża²^ORCID,Stempa Klaudia¹^ORCID,Baszuk Piotr¹²^ORCID,Bryśkiewicz Marta¹²,Cybulski Cezary¹²,Dębniak Tadeusz¹²^ORCID,Gronwald Jacek¹²^ORCID,Huzarski Tomasz¹²³,Lener Marcin R.¹,Jakubowska Anna¹,Cheriyan Angela⁴,Szwiec Marek⁵^ORCID,Stawicka-Niełacna Małgorzata³^ORCID,Godlewski Dariusz⁶,Prusaczyk Artur⁷,Jasiewicz Andrzej⁸^ORCID,Kluz Tomasz⁹^ORCID,Tomiczek-Szwiec Joanna¹⁰^ORCID,Kilar-Kobierzycka Ewa¹¹,Siołek Monika¹²,Wiśniowski Rafał¹³,Posmyk Renata¹⁴,Jarkiewicz-Tretyn Joanna¹⁵,Sun Ping⁴,Scott Rodney J.¹⁶^ORCID,Narod Steven A.⁴^ORCID,Lubiński Jan¹²^ORCID

Affiliation:

1. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland

2. Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland

3. Department of Clinical Genetics and Pathology, University of Zielona Góra, ul. Zyty 28, 65-046 Zielona Góra, Poland

4. Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto, ON M5G 1N8, Canada

5. Department of Surgery and Oncology, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland

6. OPEN, Kazimierza Wielkiego 24 St, 61-863 Poznań, Poland

7. Medical and Diagnostic Center, 08-110 Siedlce, Poland

8. Genetic Counseling Center, Subcarpatian Oncological Hospital, 18 Bielawskiego St, 36-200 Brzozów, Poland

9. Department of Gynecology, Gynecology Oncology and Obstetrics, Institute of Medical Sciences, Medical College of Rzeszow University, Rejtana 16c, 35-959 Rzeszow, Poland

10. Department of Histology, Department of Biology and Genetics, Faculty of Medicine, University of Opole, 45-040 Opole, Poland

11. Department of Oncology, District Specialist Hospital, Leśna 27-29 St, 58-100 Świdnica, Poland

12. Holycross Cancer Center, Artwińskiego 3 St, 25-734 Kielce, Poland

13. Regional Oncology Hospital, Wyzwolenia 18 St, 43-300 Bielsko Biała, Poland

14. Department of Clinical Genetics, Medical University of Bialystok, 15-089 Bialystok, Poland

15. Non-Public Health Care Centre, Cancer Genetics Laboratory, 87-100 Toruń, Poland

16. Medical Genetics, Hunter Medical Research Institute, Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Pathology North, John Hunter Hospital, King and Auckland Streets, Newcastle, NSW 2300, Australia

Abstract

Breast cancer and ovarian cancer pose a significant risk for BRCA1 carriers, with limited risk-reduction strategies. While improved screening helps in the early detection of breast cancer, preventive measures remain elusive. Emerging evidence suggests a potential link between iodine levels and modulation of cancer risk, but comprehensive studies are scarce. We conducted a prospective study among 989 BRCA1 carriers to assess the association between blood iodine levels and breast and ovarian cancer risk. Using inductively coupled plasma mass spectrometry, we measured blood iodine levels and observed a negative association with breast cancer risk, with a significantly lower risk observed in quartile 4 (iodine > 38.0 µg/L) compared with quartile 1 (iodine < 30 µg/L) (HR = 0.49; 95%CI: 0.27–0.87; p = 0.01). Conversely, a suggestive increase in ovarian cancer risk was observed at higher iodine levels (HR = 1.91; 95%CI: 0.64–5.67; p = 0.25). No significant association was found between iodine levels and overall cancer risk. Our results suggest the potential of iodine to reduce breast cancer risk in BRCA1 carriers after prophylactic oophorectomy but require further validation and investigation of its effect on ovarian cancer risk and overall mortality. These findings highlight the need for personalized strategies to manage cancer risk in BRCA1 carriers.

Funder

Minister of Science and Higher Education

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6643/16/11/1788/pdf

Reference38 articles.

1. Inheritance of Human Breast Cancer: Evidence for Autosomal Dominant Transmission in High-Risk Families;Newman;Proc. Natl. Acad. Sci. USA,1988

2. Genetic Linkage Analysis in Familial Breast and Ovarian Cancer: Results from 214 Families. The Breast Cancer Linkage Consortium;Easton;Am. J. Hum. Genet.,1993

3. Risks of Cancer in BRCA1-Mutation Carriers;Ford;Lancet,1994

4. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers;Kuchenbaecker;JAMA,2017

5. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants;Li;J. Clin. Oncol.,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antioxidant Properties of Zinc and Copper—Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers;Antioxidants;2024-07-14